eli lilly sues compounders for selling unauthorized tirzepatide copies

eli lilly sues compounders for selling unauthorized tirzepatide copies telehealth partners continue to sell compounded GLP-1 weight-loss drugs despite agreement not to Eli Lilly sues Mochi Health – Eli Lilly sues Houston-based compounding

Name: eli lilly sues compounders for selling unauthorized tirzepatide copies telehealth partners continue to sell compounded GLP-1 weight-loss drugs despite agreement not to Eli Lilly sues Mochi Health – Eli Lilly sues Houston-based compounding
Brand: actil.am
SKU: 31693836317
Price: 22.42 USD
Availability: InStock
Rating: 4.5859000000000005 (20 reviews)

SKU: 31693836317

4.6

EUR22.42 EUR53.42

Pay in 4 interest-free payments of $5.61 Learn more

Shipping Estimate
USA

USA

CAN

Ships within 48 hours · Estimated delivery Aug 31 - Sep 5

Description

Several scenarios warrant medical evaluation and discussion

By potentially dampening inflammatory processes, GLP-1 receptor agonists may help stabilise atherosclerotic plaques, improve endothelial function, and reduce thrombotic risk

However, LSM (SE) change from baseline to week 72 for EQ-VAS scores were significantly higher for the tirzepatide groups compared with placebo (tirzepatide 10 mg ( n = 281): 8.7 (0.7)